--- title: "Aditxt Enacts Reverse Stock Split to Maintain Nasdaq Listing" type: "News" locale: "en" url: "https://longbridge.com/en/news/286619614.md" description: "Aditxt has enacted a 1-for-27 reverse stock split approved by shareholders to maintain its Nasdaq listing. Effective May 15, 2026, this move reduces outstanding shares from 13.8 million to approximately 510,000, aiming to comply with Nasdaq's minimum bid price requirement. Adjustments will be made to stock options and other securities, with no action required from shareholders. The restructuring is intended to stabilize Aditxt's listing status and facilitate access to public capital markets." datetime: "2026-05-15T21:44:52.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286619614.md) - [en](https://longbridge.com/en/news/286619614.md) - [zh-HK](https://longbridge.com/zh-HK/news/286619614.md) --- # Aditxt Enacts Reverse Stock Split to Maintain Nasdaq Listing ### Claim 55% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks An announcement from Aditxt ( (ADTX) ) is now available. On May 1, 2026, Aditxt’s shareholders approved a proposal to authorize a reverse split of the company’s common stock, and the board subsequently set the ratio at 1-for-27. A certificate of amendment was filed in Delaware on May 14, 2026, making the reverse split effective as of 4:01 p.m. Eastern Time on May 15, 2026, with split-adjusted trading on Nasdaq commencing on May 18, 2026 under the existing ADTX ticker. The move, which reduced Aditxt’s outstanding shares from about 13.8 million to roughly 510,000 while keeping authorized share count and par value unchanged, is primarily aimed at regaining compliance with Nasdaq’s minimum bid price requirement. Proportionate adjustments will be made to outstanding stock options, restricted stock units, warrants, and related exercise prices, with fractional shares rounded up, while shareholders holding in book-entry or through intermediaries are not required to take any action. The reverse split also results in a new CUSIP (007025869) for Aditxt’s common stock, and the company’s transfer agent will provide stockholders of record with updated ownership information. The restructuring of the capital base could help stabilize Aditxt’s listing status on Nasdaq, a key consideration for existing investors and for the company’s ability to access public capital markets going forward. **More about Aditxt** Aditxt, Inc. is a social innovation platform focused on accelerating promising health innovations through an ecosystem of research institutions, industry partners, and shareholders. The company employs a collaborative model aimed at democratizing innovation, driving disruptive growth, and addressing significant societal challenges in the healthcare sector. Its platform-centric strategy emphasizes stakeholder participation and collective progress, positioning Aditxt as an intermediary that supports the development and scaling of health-related technologies rather than a traditional single-product biotech. This model is designed to capture value across multiple disciplines and projects within the broader health innovation landscape. **Average Trading Volume:** 2,067,684 **Technical Sentiment Signal:** Strong Sell **Current Market Cap:** $60.42K Find detailed analytics on ADTX stock on TipRanks’ Stock Analysis page. ### Related Stocks - [ADTX.US](https://longbridge.com/en/quote/ADTX.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) ## Related News & Research - [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md) - [Roivant posts unexpected Q4 profit due to Moderna lawsuit settlement gain](https://longbridge.com/en/news/287053604.md) - [Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call](https://longbridge.com/en/news/286422585.md) - [Korro Bio To Advance KRRO-111 As Potential Treatment For AATD](https://longbridge.com/en/news/287089978.md) - [Legend Biotech Q1 Solid for Carvykti, Focus Shifts to In Vivo Pipeline, RBC Says](https://longbridge.com/en/news/286290495.md)